Week Ahead In Pharma: Data Readouts Of COVID-19 Trials & FDA Decisions THOUSAND OAKS (dpa-AFX) - The development and distribution of vaccines have been making headlines amid a surge in COVID-19 cases and this past week was no exception. Novavax Inc. (NVAX), which was up 74%, was one of the top gainers for the week ending January 29, 2021, thanks to encouraging trial results of its COVID-19 vaccine candidate. In a phase III trial, conducted in UK, the two-dose regimen of Novavax vaccine NVX-CoV2373 has been found to have an efficacy rate of 89.3%. Vaxart Inc. (VXRT), with returns of nearly 68%, was another winner of the week as the company reported new pre-clinical histology data showing that its oral vaccine protected against lung inflammation in hamster models.